• At Least US$260M of Proceeds from the Business Combination, Cash and Trade Receivables to Support Prenetics Growth
• Closing of the Business Combination is Expected to Occur on May 18, 2022^[1]
• Prenetics Shares to Begin Trading on Nasdaq on May 18, 2022^[1] Under Ticker "PRE"

HONG KONG, May 11, 2022 /PRNewswire/ -- Prenetics Group Limited ("Prenetics"), a global leader in genomic and diagnostic testing, and Artisan Acquisition Corp. (Nasdaq: ARTAU, "Artisan"), a special purpose acquisition company founded by renowned cultural entrepreneur Adrian Cheng, today announced that Artisan shareholders overwhelmingly approved the previously announced business combination with Prenetics at an extraordinary general meeting of shareholders on May 9, 2022.
Complete official results of the vote were included in a Current Report on Form 8-K filed by Artisan with the Securities and Exchange Commission (the "SEC").
The business combination is expected to close on May 18, 2022, subject to the satisfaction or waiver of customary closing conditions. Following the consummation of the business combination, the combined company's securities will be traded on Nasdaq on May 18, 2022under the ticker symbol "PRE".
Recent Business Highlights
Prenetics reported record first quarter 2022 preliminary financial results on May 4, 2022. Revenue for the first quarter of 2022 was US$92.0 million, a record high, compared to US$57.5 million in the first quarter of 2021, representing a 60.2% year-on-year growth. Adjusted EBITDA (non-IFRS)^[2] was US$12.7 million compared to US$12.5 million in the first quarter of 2021.
Prenetics has a robust product pipeline and is launching a range of new products in the first half of 2022, including ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening, and Circle Snapshot, an at-home blood test with a user-friendly blood sample collection and result delivery system.
About Prenetics
Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Prevention, Diagnostics and Personalized Care — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening; provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. To learn more about Prenetics, visit www.prenetics.com.
About Artisan
Artisan is a special purpose acquisition company incorporated in the Cayman Islands for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Artisan searches globally for a target with operations or prospects focusing on high-growth healthcare, consumer and technology sectors, and companies that it believes can be well-positioned for success in Greater China.